Description
Indication & Scope
KangMeiNa® Tibremciclib Tartrate Capsules treats locally advanced or metastatic breast cancer in adult patients.
- Mechanism: Selective cyclin-dependent kinase 4/6 inhibitor, blocks tumor cell cycle progression at G1 phase, suppresses proliferation of hormone receptor-positive breast cancer cells.
- Drug class: CDK4/6 targeted anti-tumor small molecule inhibitor.
- Clinical use: Combination endocrine therapy for unresectable locally advanced or metastatic HR-positive, HER2-negative adult breast cancer.
| Generic Name | Tibremciclib Tartrate Capsules |
| Brand Name | KangMeiNa |
| Ingredient | Tibremciclib Tartrate |
| Dosage Form | Capsules |
| Package | 0.1g*7 capsules/box |
| Conditions Treated | Locally advanced breast cancer, metastatic breast cancer in adults |
| Taboos | Severe hepatic or renal insufficiency, known hypersensitivity to tibremciclib tartrate or capsule excipients, pregnant women |
| Place of origin | China |
| Prescription type | Prescription-only |
| Storage Conditions | Sealed storage at room temperature 15°C–30°C, keep away from moisture |
| Manufacturer | BeiDa Pharmaceutical Co., Ltd. |
| Registration Authority | National Medical Products Administration (NMPA), China |
| Approval number | H20250044 |
| Approval Date | Jun 30, 2025 |
| Shelf Life | 36 months |
How to use ?
Recommended Dose: 1 capsule orally once daily, continuous administration for 21 days followed by a 7-day treatment break per cycle.
Time: Take orally at fixed time every day, with or without food.
Instructions for use: Swallow the capsule whole with plain water, do not crush or chew; discontinue temporarily when grade 3/4 hematological toxicity occurs.
Interaction: Strong CYP3A4 inhibitors will elevate systemic exposure of tibremciclib, concurrent use should be avoided.
Side effects:
1. Common: neutropenia, leukopenia, fatigue, alopecia, diarrhea.
2. Severe: severe myelosuppression, interstitial lung disease, elevated transaminase.
Important Notice
This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indicatiaon, and regional regulatory requirements.
Packaging & Shipping
Packaging
Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.
Shipping Methods
Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.
Export Support
Certificate of Analysis
GMP Certificate
Commercial Invoice
Packing List & CPP
Cold Chain Logistics
Customs Documentation
Scientific and regulatory sources
FAQ
What disease does Tibremciclib Tartrate Capsules mainly treat?
It is used for the treatment of locally advanced or metastatic breast cancer in adult patients.
What is the drug class of Tibremciclib Tartrate Capsules?
It belongs to CDK4/6 targeted anti-tumor small molecule inhibitors.
Which patients cannot use Tibremciclib Tartrate Capsules?
Pregnant women, patients with severe hepatic or renal insufficiency, and hypersensitive patients are contraindicated.
What severe adverse reactions may Tibremciclib Tartrate Capsules cause?
It may cause severe myelosuppression, interstitial lung disease and elevated transaminase.
KangMeiNa® | Tibremciclib Tartrate Capsules | Breast Cancer | DengYueRX
INN: Tibremciclib Tartrate Capsules
Indications: Breast cancer
Dosage Form: Capsules
Strength: 0.1g/capsule
